{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"EBS","limit":50},"count":50,"signals":[{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":17,"context":"st& Young LLP as our independent registered public accounting firm for the fiscal year ending December31, 2026; | | | 3 | To hold, on an advisory basis, a vote to approve the 2025 compensation of our named executive officers (NEOs); | | | 4 | To approve an amendment to the Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan (the Plan) to increase the number of shares of common stock for the grant of awa","filed_date":"2026-03-20","accession":"0001367644-26-000033","full_text":"https://origin.rootz.global/static/filing/0001367644-26-000033.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":44,"context":"of Emergent BioSolutions Inc. or any of our businesses, our business strategy, future operations, future financial position, future revenues and earnings, our ability to achieve the objectives of our restructuring initiatives, acquisitions and divestitures, including our future results, projected costs, prospects, plans and objectives of management, are forward-looking statements. We generally identify forward-looking st","filed_date":"2026-02-27","accession":"0001367644-26-000015","full_text":"https://origin.rootz.global/static/filing/0001367644-26-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":66,"context":"reduce our net income. Unfavorable provisions in government contracts, some of which may be customary, may subject our business to material limitations, restrictions and uncertainties and may have a material adverse impact on our business, financial condition, operating results and cash flows. Government contracts customarily contain provisions that give the USG substantial rights and remedies, many of which are not ty","filed_date":"2026-02-27","accession":"0001367644-26-000015","full_text":"https://origin.rootz.global/static/filing/0001367644-26-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":14,"context":"h Q4 2024. The decrease was primarily due to lower marketing, professional services and legal expenses, combined with a decrease in compensation and other employee related expenses as a result of the restructuring initiatives that took place from January of 2023 through September 2025.  ADDITIONAL FINANCIAL INFORMATION(1) Capital Expenditures | | | | | | | | | | | | | | | ($ in millions) | Q4 2025 | Q4 2024 | % Change |","filed_date":"2026-02-26","accession":"0001367644-26-000012","full_text":"https://origin.rootz.global/static/filing/0001367644-26-000012.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":51,"context":"of Emergent BioSolutions Inc. or any of our businesses, our business strategy, future operations, future financial position, future revenues and earnings, our ability to achieve the objectives of our restructuring initiatives and divestitures, including our future results, projected costs, prospects, plans and objectives of management, are forward-looking statements. We generally identify forward-looking statements by us","filed_date":"2025-10-30","accession":"0001367644-25-000202","full_text":"https://origin.rootz.global/static/filing/0001367644-25-000202.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":19,"context":"lated to settlements of our securities and shareholder litigation matters. These non-recurring items were coupled with decreases in compensation and other employee related expenses as a result of the restructuring initiatives that began during the first quarter of 2023, and lower marketing, professional services and legal expenses.  3 ADDITIONAL FINANCIAL INFORMATION(1) Capital Expenditures | | | | | | | | | | | | | | |","filed_date":"2025-10-29","accession":"0001367644-25-000198","full_text":"https://origin.rootz.global/static/filing/0001367644-25-000198.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"d with respect to non-interest bearing Securities, refers to interest payable after maturity, if any.  3  **Interest Payment Date**, with respect to any Security, means the Stated Maturity of an installment of interest on such Security.  **Issuer** means Emergent BioSolutions Inc., a Delaware corporation, and, subject to Article 9, its successors and assigns.  **Issuer Order** means a written stateme","filed_date":"2025-08-07","accession":"0001193125-25-175438","full_text":"https://origin.rootz.global/static/filing/0001193125-25-175438.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":53,"context":"of Emergent BioSolutions Inc. or any of our businesses, our business strategy, future operations, future financial position, future revenues and earnings, our ability to achieve the objectives of our restructuring initiatives and divestitures, including our future results, projected costs, prospects, plans and objectives of management, are forward-looking statements. We generally identify forward-looking statements by us","filed_date":"2025-08-07","accession":"0001367644-25-000181","full_text":"https://origin.rootz.global/static/filing/0001367644-25-000181.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":21,"context":"onal services fees related to general corporate initiatives in the prior year and legal service fees, coupled with a $17.4million reduction in compensation and other employee costs as a result of the restructuring initiatives that began during the first quarter of 2023 and a decrease in marketing costs. Impairment of long-lived assets For Q2 2025, impairment of long-lived assets decreased $27.2million, or 100%, due to no","filed_date":"2025-08-06","accession":"0001367644-25-000179","full_text":"https://origin.rootz.global/static/filing/0001367644-25-000179.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":40,"context":"of Emergent BioSolutions Inc. or any of our businesses, our business strategy, future operations, future financial position, future revenues and earnings, our ability to achieve the objectives of our restructuring initiatives and divestitures, including our future results, projected costs, prospects, plans and objectives of management, are forward-looking statements. We generally identify forward-looking statements by us","filed_date":"2025-05-08","accession":"0001367644-25-000124","full_text":"https://origin.rootz.global/static/filing/0001367644-25-000124.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":15,"context":"ve Expenses For Q1 2025, SGA expenses decreased $32.3million, or 38%, as compared with Q1 2024. The decrease was primarily due to decreases in compensation and other employee costs as a result of the restructuring initiatives that began during the first quarter of 2023, a reduction in marketing costs, lower professional services fees related to general corporate initiatives in 2024, including organizational transformatio","filed_date":"2025-05-07","accession":"0001367644-25-000121","full_text":"https://origin.rootz.global/static/filing/0001367644-25-000121.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"rm. | Link executive compensation to long-term company performance.Granted in stock options (100%).Fixed amount of stock options to minimize share usage. Stock options vest in three equal annual installments over a three-year period.Stock options subject to a seven-year term. | | | | | | | Retirement and Health and Welfare BenefitsPromote healthiness and financial readiness for retirement. | Executiv","filed_date":"2025-03-21","accession":"0001367644-25-000080","full_text":"https://origin.rootz.global/static/filing/0001367644-25-000080.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":18,"context":"Young LLP as our independent registered public accounting firm for the fiscal year ending December31, 2025; and | | | 3 | To hold, on an advisory basis, a vote to approve the 2024 compensation of our named executive officers (NEOs). | | Only holders of our common stock at the close of business on March 3, 2025, the record date, are entitled to receive this notice and to attend and vote at the annual meeting. We are mail","filed_date":"2025-03-21","accession":"0001367644-25-000080","full_text":"https://origin.rootz.global/static/filing/0001367644-25-000080.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":64,"context":"of Emergent BioSolutions Inc. or any of our businesses, our business strategy, future operations, future financial position, future revenues and earnings, our ability to achieve the objectives of our restructuring initiatives and divestitures, including our future results, projected costs, prospects, plans and objectives of management, are forward-looking statements. We generally identify forward-looking statements by us","filed_date":"2025-03-04","accession":"0001367644-25-000021","full_text":"https://origin.rootz.global/static/filing/0001367644-25-000021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":65,"context":"reduce our net income. Unfavorable provisions in government contracts, some of which may be customary, may subject our business to material limitations, restrictions and uncertainties and may have a material adverse impact on our business, financial condition, operating results and cash flows. Government contracts customarily contain provisions that give the USG substantial rights and remedies, many of which are not ty","filed_date":"2025-03-04","accession":"0001367644-25-000021","full_text":"https://origin.rootz.global/static/filing/0001367644-25-000021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":21,"context":"was primarily due to lower legal services fees and consulting services fees for disputes and other corporate initiatives, coupled with lower employee related expenses and compensation as a result of restructuring initiatives during 2023 and 2024. The decrease was also driven by lower marketing fees related to the launch of OTC NARCAN in the prior year.  ADDITIONAL FINANCIAL INFORMATION(1) Capital Expenditures | | | | |","filed_date":"2025-03-03","accession":"0001367644-25-000019","full_text":"https://origin.rootz.global/static/filing/0001367644-25-000019.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":14,"context":"re performance of the Company or any of our businesses, our business strategy, future operations, future financial position, future revenues and earnings, our ability to achieve the objectives of our restructuring initiatives and divestitures, including our future results, projected costs, prospects, plans and objectives of management, are forward-looking statements. We generally identify forward-looking statements by us","filed_date":"2025-01-15","accession":"0001193125-25-007008","full_text":"https://origin.rootz.global/static/filing/0001193125-25-007008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":54,"context":"of Emergent BioSolutions Inc. or any of our businesses, our business strategy, future operations, future financial position, future revenues and earnings, our ability to achieve the objectives of our restructuring initiatives and divestitures, including our future results, projected costs, prospects, plans and objectives of management, are forward-looking statements. We generally identify forward-looking statements by us","filed_date":"2024-11-07","accession":"0001367644-24-000178","full_text":"https://origin.rootz.global/static/filing/0001367644-24-000178.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":24,"context":"istrative Expenses For Q3 2024, SGA expenses decreased $9.4million, or 11%, as compared with Q3 2023. The decrease was primarily due to lower employee related expenses and compensation as a result of restructuring initiatives during 2023 and 2024, coupled with a decrease in legal services fees for disputes and other corporate initiatives. This decrease was partially offset by the settlement charge related to the stockhol","filed_date":"2024-11-06","accession":"0001367644-24-000176","full_text":"https://origin.rootz.global/static/filing/0001367644-24-000176.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":49,"context":"of Emergent BioSolutions Inc. or any of our businesses, our business strategy, future operations, future financial position, future revenues and earnings, our ability to achieve the objectives of our restructuring initiatives, including our future results, projected costs, prospects, plans and objectives of management, are forward-looking statements. We generally identify forward-looking statements by using words like \"a","filed_date":"2024-08-07","accession":"0001367644-24-000147","full_text":"https://origin.rootz.global/static/filing/0001367644-24-000147.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":24,"context":"nistrative Expenses For Q2 2024, SGA expenses decreased $5.5million, or 6%, as compared with Q2 2023. The decrease was primarily due to lower employee related expenses and compensation as a result of restructuring initiatives during 2023, coupled with a decrease in marketing expense. The decrease was partially offset by higher legal services fees for disputes and other corporate initiatives, as well as higher restructuri","filed_date":"2024-08-06","accession":"0001367644-24-000142","full_text":"https://origin.rootz.global/static/filing/0001367644-24-000142.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":38,"context":"of Emergent BioSolutions Inc. or any of our businesses, our business strategy, future operations, future financial position, future revenues and earnings, our ability to achieve the objectives of our restructuring initiatives, including our future results, projected costs, prospects, plans and objectives of management, are forward-looking statements. We generally identify forward-looking statements by using words like \"a","filed_date":"2024-05-02","accession":"0001367644-24-000063","full_text":"https://origin.rootz.global/static/filing/0001367644-24-000063.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":18,"context":"ve Expenses For Q1 2024, SGA expenses decreased $16.6million, or 16%, as compared with Q1 2023. The decrease was primarily due to decreases in compensation and other employee costs as a result of the restructuring initiatives that began during the first quarter of 2023 and a reduction in professional services fees related to general corporate initiatives in the prior year, including organizational transformation consulti","filed_date":"2024-05-01","accession":"0001367644-24-000060","full_text":"https://origin.rootz.global/static/filing/0001367644-24-000060.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"ronmental impacts are similarly addressed through opportunities to improve the sustainability of our operations and innovate our environmental stewardship strategy. Risk mitigation also includes fulfillment of our regulatory compliance obligations. Finally, we challenge ourselves to continually improve, by setting goals, monitoring performance, and evolving systematically to achieve excellence. Susta","filed_date":"2024-04-11","accession":"0001193125-24-093400","full_text":"https://origin.rootz.global/static/filing/0001193125-24-093400.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":21,"context":"Young LLP as our independent registered public accounting firm for the fiscal year ending December31, 2024; | | |  3. |  To hold, on an advisory basis, a vote to approve the 2023 compensation of our named executive officers (NEOs); and | | |  4. |  To approve an amendment of the Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan. | | We are mailing this notice beginning on or about April 11, 2024 with","filed_date":"2024-04-11","accession":"0001193125-24-093400","full_text":"https://origin.rootz.global/static/filing/0001193125-24-093400.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":31,"context":"e projects for a variety of third-party customers, including government agencies, innovative pharmaceutical companies, and non-government organizations. In August 2023, we initiated an organizational restructuring plan (the August 2023 Plan) which included actions to reduce investment in and de-emphasize focus on our Bioservices business.Other Strategic ActivitiesJanuary 2023 Organizational Restructuring PlanIn Jan","filed_date":"2024-03-08","accession":"0001367644-24-000033","full_text":"https://origin.rootz.global/static/filing/0001367644-24-000033.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":65,"context":"reduce our net income. Unfavorable provisions in government contracts, some of which may be customary, may subject our business to material limitations, restrictions and uncertainties and may have a material adverse impact on our business, financial condition, operating results and cash flows. Government contracts customarily contain provisions that give the USG substantial rights and remedies, many of which are not ty","filed_date":"2024-03-08","accession":"0001367644-24-000033","full_text":"https://origin.rootz.global/static/filing/0001367644-24-000033.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":19,"context":"d $3.7million, or 4%, as compared with Q4 2022. The decrease was primarily due to decreases in consulting and contracted services and decreases in compensation and other employee costs related to the restructuring initiatives taken during 2023. The decrease was partially offset by an increase in marketing expenses related to the launch of OTC NARCAN and higher professional services fees related to legal remediation servi","filed_date":"2024-03-06","accession":"0001367644-24-000026","full_text":"https://origin.rootz.global/static/filing/0001367644-24-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":29,"context":", lyophilization, final packaging and stability studies, as well as manufacturing of vial and pre-filled syringe formats on multiple platforms. In August 2023, the Company initiated an organizational restructuring plan (the August 2023 Plan) which included actions to reduce investment in and de-emphasize focus on its CDMO services business. 2. Summary of significant accounting policies Basis of presentation and con","filed_date":"2023-12-11","accession":"0001367644-23-000208","full_text":"https://origin.rootz.global/static/filing/0001367644-23-000208.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":39,"context":"able. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition. On April 20, 2021, May 14, 2021, and June 2, 2021, putative class action lawsuits were fi","filed_date":"2023-12-11","accession":"0001367644-23-000208","full_text":"https://origin.rootz.global/static/filing/0001367644-23-000208.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":42,"context":"reduce our net income. Unfavorable provisions in government contracts, some of which may be customary, may subject our business to material limitations, restrictions and uncertainties and may have a material adverse impact on our business, financial condition, operating results and cash flows. Government contracts customarily contain provisions that give the USG substantial rights and remedies, many of which are not ty","filed_date":"2023-12-11","accession":"0001367644-23-000207","full_text":"https://origin.rootz.global/static/filing/0001367644-23-000207.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":13,"context":"angible assets | 16.3 | | | | Total operating expenses | $ | 512.6 | | | | | | | Restructuring Expenses During Q3 2023, the Company incurred restructuring expense in connection with an organizational restructuring plan (the August 2023 Plan) announced on August 8, 2023. The Company incurred approximately $20.5million in charges in connection with the August 2023 Plan during Q3 2023. These charges consisted primaril","filed_date":"2023-11-08","accession":"0001367644-23-000182","full_text":"https://origin.rootz.global/static/filing/0001367644-23-000182.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":18,"context":"1.5 | | | | Furniture and equipment | 117.5 | | | | Software | 0.3 | | | | Construction-in-progress | 107.4 | | | | Total impairment on long-lived assets | $ | 306.7 | | | January 2023 Organizational Restructuring Plan In January 2023, the Company initiated an organizational restructuring plan (the January 2023 Plan) intended to reduce operating costs, improve operating margins, and continue advancing the Companys","filed_date":"2023-08-09","accession":"0001367644-23-000155","full_text":"https://origin.rootz.global/static/filing/0001367644-23-000155.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":36,"context":"able. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition. On April 20, 2021, May 14, 2021, and June 2, 2021, putative class action lawsuits were fi","filed_date":"2023-08-09","accession":"0001367644-23-000155","full_text":"https://origin.rootz.global/static/filing/0001367644-23-000155.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":56,"context":"e to an earlier date, in which case they shall be true and correct in all material respects as of such earlier date; provided that any representation and warranty that is qualified as to materiality, Material Adverse Effect or similar language shall be true and correct (after giving effect to any qualification therein) in all respects on such respective dates; (B) after giving effect to this Amendment, no Default or Eve","filed_date":"2023-05-18","accession":"0001193125-23-147301","full_text":"https://origin.rootz.global/static/filing/0001193125-23-147301.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":16,"context":"ompensation | | 6.9 | | | | Other current liabilities | | 2.4 | | | | Deferred tax liability | | 3.9 | | | | Other liabilities | | 8.7 | | | | Total liabilities held for sale | | $ | 37.5 | | | 13 4. Restructuring costs 2023 Organizational Restructuring Plan In January 2023, the Company initiated an organizational restructuring plan (the 2023 Plan) intended to reduce operating costs, improve operating margins, and c","filed_date":"2023-05-10","accession":"0001367644-23-000088","full_text":"https://origin.rootz.global/static/filing/0001367644-23-000088.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":37,"context":"able. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition. On April 20, 2021, May 14, 2021, and June 2, 2021, putative class action lawsuits were fi","filed_date":"2023-05-10","accession":"0001367644-23-000088","full_text":"https://origin.rootz.global/static/filing/0001367644-23-000088.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"Young LLP as our Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2023; | | |  3. |  To hold, on an advisory basis, a vote to approve the 2022 compensation of our named executive officers (NEOs); | | |  4. |  To hold, on an advisory basis, a vote on the frequency of future stockholder advisory votes on the compensation of our NEOs; | | |  5. |  To approve an amendment of our stock in","filed_date":"2023-04-14","accession":"0001193125-23-102074","full_text":"https://origin.rootz.global/static/filing/0001193125-23-102074.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":26,"context":"ott-Rodino Antitrust Improvements Act of 1976, as amended, (2) receipt of required clearances and approvals under Spains competition laws, (3) receipt of certain Swiss real property approvals, (4) no material adverse effect having occurred with respect to the business, and (5) certain other customary conditions. Services Segment CDMO Services Our portfolio of CDMO services consists of three distinct but interrelated ser","filed_date":"2023-03-01","accession":"0001367644-23-000046","full_text":"https://origin.rootz.global/static/filing/0001367644-23-000046.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"able. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition. On April 20, 2021, May 14, 2021, and June 2, 2021, putative class action lawsuits were fi","filed_date":"2022-11-09","accession":"0001367644-22-000144","full_text":"https://origin.rootz.global/static/filing/0001367644-22-000144.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"11 EMERGENT BIOSOLUTIONS INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited, in millions, except share and per share amounts) having been issued; (vii) and there having occurred no material adverse effect on the assets being sold in the Transaction. Closing of the Transaction is currently expected to occur during the third quarter of 2022. 2.Basis of presentation and principles of consolidation Basis","filed_date":"2022-08-02","accession":"0001367644-22-000119","full_text":"https://origin.rootz.global/static/filing/0001367644-22-000119.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":18,"context":"....................................................................... 34 5.7 BARDA Consent ................................................................................................ 34 5.8 No Material Adverse Effect ............................................................................... 34 5.9 Frustration of Closing Conditions .................................................................... 34 6. Con","filed_date":"2022-05-18","accession":"0001367644-22-000075","full_text":"https://origin.rootz.global/static/filing/0001367644-22-000075.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"able. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition. On June 29, 2021, Lincolnshire Police Pension Fund (Lincolnshire) and on August 16, 2021,","filed_date":"2022-04-29","accession":"0001367644-22-000070","full_text":"https://origin.rootz.global/static/filing/0001367644-22-000070.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":15,"context":"executive officers; | | |  |  |  Determining the compensation of our chief executive officer and, formerly, the executive chairman; | | |  |  |  Reviewing and approving the compensation of our other named executive officers; | | |  |  |  Overseeing the evaluation of our senior executives; | | |  |  |  Overseeing and administering our cash and equity incentive plans and employee stock purchase plan; | | |  |  |  Reviewi","filed_date":"2022-04-15","accession":"0001193125-22-106880","full_text":"https://origin.rootz.global/static/filing/0001193125-22-106880.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":".  We may fail to capitalize on the most scientifically, clinically or commercially promising or profitable product candidates. Due to numerous factors, the COVID-19 coronavirus pandemic could have a material adverse impact on our business, results of operations and financial performance, including: Changes in government priorities resulting from the pandemic and supply chain shortages could impact our overall business.","filed_date":"2022-02-25","accession":"0001367644-22-000024","full_text":"https://origin.rootz.global/static/filing/0001367644-22-000024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":15,"context":"ary 15, 2022, the Compensation Committee (the Committee) of the Board of Directors of Emergent BioSolutions Inc. (the Company) approved certain actions with respect to the compensation of the current named executive officers of the Company (the Named Executive Officers), as listed in the Definitive Proxy Statement related to its 2021 Annual Meeting of Stockholders. Annual Compensation Assessment of Named Executive Offic","filed_date":"2022-02-22","accession":"0001367644-22-000009","full_text":"https://origin.rootz.global/static/filing/0001367644-22-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":21,"context":".  We may fail to capitalize on the most scientifically, clinically or commercially promising or profitable product candidates. Due to numerous factors, the COVID-19 coronavirus pandemic could have a material adverse impact on our business, results of operations and financial performance, including: Changes in government priorities resulting from the pandemic, supply chain shortages and changing employee working arrange","filed_date":"2021-11-05","accession":"0001367644-21-000137","full_text":"https://origin.rootz.global/static/filing/0001367644-21-000137.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":21,"context":"following risks or of unknown risks and uncertainties may adversely affect our business, operating results and financial condition.  RISK FACTOR SUMMARY The COVID-19 coronavirus pandemic could have a material adverse impact on our business, results of operations and financial performance. In addition, there are a number of government contracting risks that could impact our business, financial condition, operating result","filed_date":"2021-07-30","accession":"0001367644-21-000115","full_text":"https://origin.rootz.global/static/filing/0001367644-21-000115.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":21,"context":"following risks or of unknown risks and uncertainties may adversely affect our business, operating results and financial condition.  RISK FACTOR SUMMARY The COVID-19 coronavirus pandemic could have a material adverse impact on our business, results of operations and financial performance. In addition, there are a number of government contracting risks that could impact our business, financial condition, operating result","filed_date":"2021-04-30","accession":"0001367644-21-000073","full_text":"https://origin.rootz.global/static/filing/0001367644-21-000073.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EBS","company":"Emergent BioSolutions Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":75,"context":"particular matter, it will have no effect on the ratification of the appointment of Ernst YoungLLP as our Independent Registered Public Accounting Firm or the advisory vote on the compensation of our named executive officers or the vote on the amendment of our stock incentive plan. Does the company offer an opportunity to receive future proxy materials electronically Yes. If you vote on the internet, simply follow the p","filed_date":"2021-04-09","accession":"0001367644-21-000061","full_text":"https://origin.rootz.global/static/filing/0001367644-21-000061.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"e018a1c1ee49ad019cfbf1a12f26288e1eec0ac3da04d5e8b747953c82a2d4f2","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"b251db88a661c7dcecfc48f5e91090a1cbcf27ee17a79b810dfa225639a018a3","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":461,"hourly_limit":500,"remaining":39,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}